Non-allogeneic immunotherapy in acute myeloid leukaemia

Mené sur 44 patients atteints d'une leucémie myéloïde aiguë ou d'un syndrome myélodysplasique à haut risque, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité de l'ajout de nivolumab à une chimiothérapie d'induction combinant idarubicine et cytarabine

Résumé en anglais

Over the past thirty years, substantial progress has been made in understanding the pathophysiology of acute myeloid leukaemia, leading to better therapeutic strategies and substantial improvement in the treatment outcome. Nevertheless, treatment for young patients is often still based on stem-cell transplantation preceded by intensive chemotherapy, to which new molecules are sometimes added, such as gemtuzumab ozogamicin or FLT3 inhibitors, two approved drugs in this setting.